Yangfan Plan Neurointervention Special Session Roadshow: Exploring Innovation and Development in the Next Phase of the Industry

WithNeurointerventional SurgeryofIncreasing Popularity，Market SizeGraduallyVolume Expansion，ChinaDomestic RelatedLeveraging advantages in products, technology, cost, and localization, companies are rapidly capturing share in the neurointerventional market.FutureThe neurointerventional market will accelerate the completion of domestic substitution, mirroring the trajectory of the coronary stent market.

Pain points breed opportunities, and the times make heroes. To better discover outstanding innovative projects in neurointervention, accelerate the development of domestic neurointervention enterprises, and promote the healthy and orderly growth of the industry, under the guidance of the Science and Technology Innovation Bureau of Guangming District, Shenzhen, hosted by China Merchants Shekou Industrial Zone Holdings Co., Ltd., and organized by VCBeatYangfan Plan Investment and Financing Roadshow — [Neurointerventional] Special Session Offline Closed-Door MeetingMeetingwill beSeptember 22, 13:00Officially Held。

Event Registration:This event will be held as an offline, closed-door meeting, with attendance limited to 80 participants.

Registration Method：http://hdxu.cn/y9HiV   Or scan the QR code to register.

1. Mino Microinvasive

Shenzhen Meinuo Minimally Invasive Medical Technology Co., Ltd. was founded in 2017 by a team of returnees. It is a high-tech enterprise dedicated to the research and development, production, and sales of neurovascular interventional medical devices, offering a comprehensive portfolio of interventional products for stroke treatment.

The company’s R&D operations are based in the United States, its business operations in Shanghai and Beijing, and its manufacturing in Shenzhen. The company has established an R&D center responsible for product design, process and equipment development, clinical research, product registration, and intellectual property management. Its high-caliber R&D team is dedicated to the development of innovative neurovascular interventional medical devices and related technologies. The company emphasizes extensive collaboration and exchange with renowned physicians and technical experts both domestically and internationally, implementing intellectual property controls throughout the entire R&D process. Currently, it employs senior R&D professionals holding overseas doctoral and master’s degrees.

2. Shenping Medical

Zhuhai Shenping Medical Co., Ltd. was established in August 2016 and is located at No. 2 Gangwan, High-Tech Industrial Development Zone, Zhuhai City. It is a high-tech enterprise focused on the industrialization of stroke (cerebral apoplexy) medical treatments.The company currently operates a manufacturing facility spanning over 2,000 square meters, equipped with Class 10,000 (ISO Class 7) cleanrooms, a microbiology laboratory, and a physicochemical laboratory. Its product pipeline covers three major segments: ischemic stroke, hemorrhagic stroke, and neurovascular access devices. The company has independently developed a series of products, including coil systems, liquid embolic systems, thrombectomy devices, and catheters.

The company’s founder has over two decades of experience in the neurointerventional field, and core team members hail from several well-known domestic medical device enterprises, each possessing more than 10 years of experience in medical device product R&D or quality management.

3. Nuanyang Medical

Nuanyang Medical is a manufacturer specializing in the research, development, and production of minimally invasive implantable and interventional medical devices for the treatment of cardiovascular and cerebrovascular diseases, with R&D and manufacturing centers established in both Jiangsu and Shanghai. Nuanyang Medical’s product portfolio encompasses four major categories: neurointerventional, peripheral interventional, materials, and robotics.

The company’s core team possesses over a decade of industry experience and resources, with a strong emphasis on innovation and product excellence. Guided by clinical needs, the company has comprehensively developed a portfolio spanning three major categories of neurointerventional products: hemorrhagic, ischemic, and access devices. Furthermore, it has established a translation platform based on shared technological pathways across its product lines and forged close collaborations with renowned hospitals, universities, and key laboratories in China. Notably, the YonFlow flow diverter stent, independently developed by the team, is currently undergoing clinical trials and is poised to become the world’s first fully retrievable minimally invasive interventional device for intracranial aneurysms.

4. NeuroCare

Beijing NeuroCare Medical Co., Ltd. was established in 2016. The company is dedicated to providing comprehensive technical solutions for brain diseases, serving human brain health, saving patients' lives, and improving their quality of life. Currently, it has approved products or strategic layouts (with development at the forefront) across the full spectrum of neurovascular disease product categories, including hemorrhagic stroke, acute ischemic stroke, intracranial atherosclerotic stenosis, and access device series. The company strives to become a global provider of comprehensive solutions for patients with brain diseases.

5. Zenith Vascular

Suzhou Zenith Vascular Co., Ltd. was established in 2018. Recognized as a Science and Technology Leading Talent Enterprise in Suzhou Industrial Park, a National High-Tech Enterprise, and one of Suzhou’s “Unicorn” Cultivation Enterprises in 2021, the company is committed to becoming an industry-leading provider of vascular disease solutions. With a global perspective, Zenith Vascular collaborates with international experts in vascular interventional therapy and local elites for joint research and development. Upholding its mission of “Innovative Technology, Simplifying Vascular Treatment,” the company achieves “Me-better or First-in-Class” medical device innovations through continuous innovation. By insisting on fully independent manufacturing and constantly improving its quality system, Zenith Vascular is dedicated to delivering high-quality domestically produced products. Through localization and specialization, the company strives to align with world-leading technologies, thereby benefiting more patients with vascular diseases.

China Merchants Shekou Industrial Zone Holdings Co., Ltd. was established in 1979. Its industrial park segment is deeply engaged in the development and operation of industrial parks, currently deploying three major product lines across China: Wanggu, Yiku, and Smart City. The company holds 4.75 million square meters of industrial park assets, comprising a total of 25 park projects. Adhering to the full value chain of “integration, investment, construction, management, and exit” for park development and operations, the company implements precise, tailored strategies (“one park, one policy”) for its 25 parks nationwide. It is committed to building core competencies in spatial planning, industrial organization, ecosystem operation, innovation incubation, and industry-finance integration.

China Merchants Shekou Industrial Park has garnered widespread market recognition by leveraging its comprehensive strengths in development models, asset scale, industrial operations, industry cultivation, and innovation incubation, with its brand influence ranking among the industry leaders.

China Merchants Shekou’s industrial parks will next focus on building fourth-generation parks underpinned by digital and low-carbon operations, enhancing the “INPARK” digital operation service platform by integrating the park BI system, industry management system, smart operation system, and smart service system to empower the growth of tenant enterprises. Meanwhile, the industrial parks will position their business as “regional development enablers, comprehensive operation service providers, and innovators driving industrial advancement,” with the vision of becoming “leaders in the integrated development of cities and industries.” By proactively aligning with the national 14th Five-Year Plan strategy and closely linking national needs with China Merchants’ capabilities, they will lead industrial, consumption, and urban upgrades in the areas where their parks are located, fulfilling China Merchants Shekou’s vision and mission as an “enabler of better lives.”

VCBeat, founded in 2014, is a novel industry service provider that leverages data as its foundation, research as its core, and brand media as its connector to facilitate the precise aggregation of industrial resources and accelerate the growth of industry changemakers. It offers services such as brand communication, research consulting, data monitoring, and resource/project matchmaking to enterprises, government industrial parks, investment institutions, and other stakeholders across the industry chain.